The goal of this study was to complete the first Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) based systematic review of dupilumab use in patients living with human immunodeficiency virus (HIV).
Methods
A systematic literature review was performed using PubMed, Google Scholar, Ovid MEDLINE, and Science Direct databases as well as an internal review using University of Virginia’s electronic medical record system. All reports of dupilumab use in patients with confirmed HIV were included.
Results
14 published cases comprising 23 patients were identified and included in the review. Additionally, four unpublished cases from our own institution were included for a final cohort of 27 patients. A total of 25 patients (96%) were observed to have a clinical response, defined as improvement or complete resolution of their cutaneous or asthmatic symptoms. In 100% of patients, viral load improved or did not change, and in 80% of patients, CD4 counts remained stable. Side effects occurred in 48% of patients but were self-limited.
Discussion and Conclusions
All reported cases indicate that dupilumab is safe in patients with HIV with stable CD4 counts and low viral loads. Most patients had significant improvement within 2 months of treatment with mild side effects.
GooderhamMJHongHC-HEshtiaghiP, et al.Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol2018; 78(3 Suppl 1): S28–S36. DOI: 10.1016/j.jaad.2017.12.022.
3.
A randomized, double blind, placebo-controlled, multi-center, parallel group study to evaluate the efficacy and safety of dupilumab in patients with prurigo nodularis who are inadequately controlled on topical prescription therapies or when those therapies are not advisable, https://clinicaltrials.gov/ct2/show/NCT04183335 (updated February 17 2022. accessed June 23 2022).
4.
Study of dupilumab. (REGN668/SAR231893) monotherapy administered to adult patients with moderate-to-severe atopic dermatitis (SOLO 2). ClinicalTrials.gov Identifier: NCT02277769, https://clinicaltrials.gov/ct2/show/NCT02277769 (updated June 2 2020, accessed 17 December 2021).
AlawadhiAKaribayevaDGottliebAB. Dupilumab in HIV-positive patients: a case series report of 4 patients. JAAD Case Rep2020; 6(12): 1356–1359. DOI: 10.1016/j.jdcr.2020.09.023.
7.
MollanazarNKQiuCCAldrichJL, et al.Use of dupilumab in patients who are HIV‐positive: report of four cases. Br J Dermatol2019; 181(6): 1311–1312. DOI: 10.1111/bjd.18222.
8.
FowlerERosenJLev-TovH, et al.Two cancer patients receiving dupilumab for treatment of atopic dermatitis. Acta Derm Venereol2019; 99(10): 899–900. DOI: 10.2340/00015555-3201.
9.
NusbaumKBKaffenbergerBHParadiso BsMM, et al.Dupilumab for treatment of atopic dermatitis in patients living with HIV: a case series. Int J Dermatol2021; 60(9): e344–e346. DOI: 10.1111/ijd.15471.
10.
Ordóñez‐RubianoMFRubiano‐MojicaPCCasasM. Young HIV‐positive male patient with severe atopic dermatitis on dupilumab and SARS‐CoV‐2 infection, a pioneer hypothesis. Int J Dermatol2021; 60(4): 514–515. DOI: 10.1111/ijd.15499.
11.
DoolanBJYeonJBakerDA, et al.Dupilumab therapy for atopic dermatitis in people living with HIV. AIDS Res Hum Retroviruses2022; 38(2): 76–79. DOI: 10.1089/aid.2021.0113.
12.
AvalloneGTrunfioMGiuraMT, et al.Dupilumab in HIV-positive patients with atopic dermatitis: a long-term follow-up patient and a literature review. Dermatol Online J2021; 27(8). DOI: 10.5070/D327854709.
13.
MarksDHPiantadosiALPatilSU, et al.Successful use of dupilumab for recalcitrant atopic dermatitis in an HIV patient. Dermatitis2019; 30(4): 276–277. DOI: 10.1097/DER.0000000000000501.
14.
RomagnuoloMAngileriLTavecchioS, et al.Safety and efficacy of dupilumab in a patient with severe atopic dermatitis and HIV infection, with 15 months of follow‐up. Clin Exp Dermatol2020; 45(6): 762–763. DOI: 10.1111/ced.14278.
15.
BrodskaPPanznerPSedlacekD, et al.Use of dupilumab in a patient with atopic dermatitis, severe asthma, and HIV infection. Dermatol Ther2020; 33(6): e14159. DOI: 10.1111/dth.14159.
16.
LorMVillaNHollandV. Safe and effective treatment of atopic dermatitis using dupilumab over 23 months in a patient with HIV. Dermatol Ther2020; 33(6): e14271. DOI: 10.1111/dth.14271.
17.
OlbrichtNKromerCForkelS, et al.Effective treatment of atopic dermatitis with dupilumab in an HIV‐positive patient. J Dtsch Dermatol Ges2020; 18(12): 1488–1490. DOI: 10.1111/ddg.14244.
18.
LiGBerkenstockMSoibermanU. Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis. Am J Ophthalmol Case Rep2020; 19: 100848. DOI: 10.1016/j.ajoc.2020.100848.
19.
BianchelliTCampanatiASapigniC, et al.The effect of dupilumab in an HBV-HIV coinfected atopic patient: a case report. Acta Dermatovenerol Alp Pannonica Adriat2021; 30(2): 71–73. DOI: 10.15570/actaapa.2021.17.
20.
GargTSankeS. Inflammatory dermatoses in human immunodeficiency virus. Indian J Sex Transm Dis AIDS2017; 38(2): 113–120. DOI: 10.4103/ijstd.IJSTD_22_17.
21.
WrightDNNelsonRPLedfordDK, et al.Serum IgE and human immunodeficiency virus (HIV) infection. J Allergy Clin Immunol1990; 85(2): 445–452. DOI: 10.1016/0091-6749(90)90154-v.
22.
Israël-BietDLabrousseFTouraniJM, et al.Elevation of IgE in HIV-infected subjects: a marker of poor prognosis. J Allergy Clin Immunol1992; 89(1 Pt 1): 68–75. DOI: 10.1016/s0091-6749(05)80042-9.
23.
ClericiMShearerGM. A TH1→TH2 switch is a critical step in the etiology of HIV infection. Immunol Today1993; 14(3): 107–111. DOI: 10.1016/0167-5699(93)90208-3.
24.
MaggiEGiudiziMGBiagiottiR, et al.Th2-like CD8+ T cells showing B cell helper function and reduced cytolytic activity in human immunodeficiency virus type 1 infection. J Exp Med1994; 180(2): 489–495. DOI: 10.1084/jem.180.2.489.
25.
LiRDuffeeDGbadamosi-AkindeleMF. CD4 count. In: StatPearls. Treasure Island, FL: StatPearls Publishing, 2021, http://www.ncbi.nlm.nih.gov/books/NBK470231/ (accessed 29 December 2021).
26.
HallingASLoftNSilverbergJI, et al.Real-world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta-analysis. J Am Acad Dermatol2021; 84(1): 139–147. DOI: 10.1016/j.jaad.2020.08.051.
27.
Husein-ElAhmedHSteinhoffM. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response. J Dermatol Treat2020; 33: 1547–1553. DOI: 10.1080/09546634.2020.1853024.
28.
SmithMPLyKThibodeauxQ, et al.Dupilumab for the treatment of severe photodermatitis. JAAD Case Rep2019; 5(7): 614–616. DOI: 10.1016/j.jdcr.2019.05.006.
29.
RabeKFNairPBrusselleG, et al.Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med2018; 378(26): 2475–2485. DOI: 10.1056/NEJMoa1804093.
